The investor is a Venture Capital firm based in San Francisco California. The firm is interested in making equity investments into early stage companies with investments ranging from $1M to $15 million per company, depending on the companies needs and stage of development. The firm is currently seeking investment opportunities throughout the United States.

The firm is looking for companies operating in Precision medicine, MedTech and medicine at the edge, AI-enabled services such as drug discovery and clinical trial support, and synthetic biology with a software component. The firm is entirely opportunistic in terms of indication and will consider companies at all stages of development.

The firm is looking for privately held companies with strong management teams. The firm is able to provide entrepreneurs with a 200-person advisory network and bring deep operational expertise.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The venture studio located in New York City. In addition to its core venture creation function, the group in early-stage digital health companies looking to enter the US market for which its platform can offer catalytic growth. In addition to providing capital, the firm assists companies with regulatory approval and commercialization in the US, through their unique company creation partnership with a large health system.

The firm invests across the spectrum of digital health, with a particular focus on companies developing AI-based technologies, virtual care and other health-related technologies.

The firm generally seeks to work hand-in-hand with management to drive value creation and assist portfolio companies with US market entry. They work with pre-revenue companies, as well as with those that are more advanced internationally and looking to enter the US market. The firm considers both minority investments and acquisitions.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The seed-stage VC fund headquartered on the West Coast and founded in 2020. The firm focuses exclusively on pediatrics, and will invest in all sectors. The firm invests out of an evergreen fund, and looks to invest $500k-1M in US-based companies that have raised some non-dilutive capital. Many of the firm’s portfolio companies come from The firm’s connections with incubators and universities. For stage of development, the firm prefers for device companies to have hit initial regulatory milestones, and for diagnostics and digital health companies to have had a pilot study. For therapeutics, the firm has a strong interest in repurposed drugs.

While the firm is agnostic to sector and subsector, they will only invest in companies whose primary indication is related to pediatrics, including orphan indications.

The firm is an active investor, and likes to play a role in helping the company advance. They tend to co-invest, and generally do not require a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A leading European Venture Capital firm investing in early-and growth stage life science companies is focused on investing in the most promising life science companies in the fields of biotechnology, therapeutics, medical technology, diagnostics and digital health. With funds totaling EUR 1.0 billion, the firm has been actively supporting world class private companies translating true innovation into successful businesses with exceptional growth. To date, the firm has invested in over 50 innovative life science companies. Initial ticket size ranges between EUR 5-10 million and up to EUR 20 million over the life of the investment.

The firm invest mainly in Europe and selectively in US across five broad areas:  Therapeutics, Medtech, Diagnostics, Digital Health and Biotechnology and R&D tools. Regarding therapeutics, the firm focuses on early-stage companies with preclinical proof of concept data or about to enter the clinic, with a preference for companies developing highly innovative technology platforms, or with early clinical data. In the other fields, the firm prefers companies with product candidates (with strong IP protection) approaching regulatory approval or companies who have already launched a first product and have some early market traction in the single million digit range.

The firm typically requests a board seat and looks for a strong and experienced management team while supporting highly talented entrepreneurs.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A Venture Capital company based in USA has raised 3 funds to date and is currently investing out of its 3rd that closed at $20M. The firm makes primarily equity investments ranging from $250,000 to $5 million over the lifetime of the investment, with $100K-$500K as an initial investment. The firm has long term relationships with several Japanese medical technology corporations and also looks for ventures that they can introduce into the Japanese market. The firm prefers to invest in companies located in the West coast of the US, although they are also open to review opportunities in North America.

The firm is looking for seed and early-stage medical device and diagnostic companies. In these areas, the firm is most interested in single use therapeutic devices. The preferred regulatory pathway is a 510(k) submission, but PMA applications are also considered. Sectors with the most interest would be interventional cardiovascular and neurovascular devices, less invasive surgical instrumentation, and point of care diagnostics. The firm remains open-minded to other types of devices and indications as well.

The firm looks for professionalism in a venture’s management team and is willing to work with firms that do not yet have a complete management team in place. The firm does not always look to take a board seat in portfolio companies, however they look to add value by developing corporate partnerships in Japan at the appropriate time.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A Life Science focused private equity and venture capital firm based in Asia manages an evergreen fund, and generally makes longer term investments than a typical VC.  The firm does not make seed investments, but is interested in both early stage venture capital investments and late stage companies seeking growth and expansion capital. Typically, the firm invests USD 5-15 million per opportunity. The firm can invest globally and is actively seeking new investment opportunities.

The firm seeks to invest in breakthrough healthcare biotech, medical devices, diagnostics, healthcare IT, and biorenewable and bioindustrial technologies. The firm is open to a wide range of technologies including novel techniques such as stem cells and genomics, and will consider investing in any area of medicine. The firm prefers to invest in technologies that have attained clinical validation.

The firm seeks a strong and experienced management team. The firm may take a board seat on a case by case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital investment firm is actively seeking medtech investment opportunities from Seed to Series B financing rounds, though the firm’s sweet spot is leading Series A investments. Initial check sizes can largely vary; the firm can invest anywhere from €1-5M, and seeks to invest €4-8M over the life of investment. With the current fund, the firm manages 5 portfolio companies, and seeks to invest in ~12 companies, for which the firm estimates 2/3 will be Europe/Israel-based companies, and 1/3 will be USA-based companies. Currently, the firm is not evaluating opportunities outside of USA, Europe, and Israel.

The firm is focused on investing in innovative medical devices that address cardiovascular or neurovascular disease. The firm does not invest in other sectors such as therapeutics, diagnostics, or digital health. Within medical devices, the firm is open to both pre-clinical (prototype) and clinical technologies. The firm has primarily evaluated PMA devices but is open to 510k regulatory pathways. The firm may consider other types of devices on a highly selective basis, but even such opportunities must have some connection or relevance to cardiovascular disease.

The firm prefers to lead investment rounds and seek board representation, though the firm can also co-invest alongside syndicates. Through the firm’s relationship with a proprietary commercialization and distribution platform, the firm is uniquely positioned to create value for their portfolio companies in the European market. Through this sister company relationship, the firm has access to a wide network including over 200 European hospitals, clinical sites, physicians, KOLs, etc. and can provide strategic advice on market strategy (EU clinical trials, regulatory process, reimbursement).

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.